Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 2
2010 1
2011 1
2013 2
2014 2
2017 2
2018 2
2019 1
2020 1
2021 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Elastic titin properties and protein quality control in the aging heart.
Salcan S, Bongardt S, Monteiro Barbosa D, Efimov IR, Rassaf T, Krüger M, Kötter S. Salcan S, et al. Among authors: bongardt s. Biochim Biophys Acta Mol Cell Res. 2020 Mar;1867(3):118532. doi: 10.1016/j.bbamcr.2019.118532. Epub 2019 Aug 14. Biochim Biophys Acta Mol Cell Res. 2020. PMID: 31421188 Free article.
Efficacy and safety of lacosamide in painful diabetic neuropathy.
Ziegler D, Hidvégi T, Gurieva I, Bongardt S, Freynhagen R, Sen D, Sommerville K; Lacosamide SP743 Study Group. Ziegler D, et al. Among authors: bongardt s. Diabetes Care. 2010 Apr;33(4):839-41. doi: 10.2337/dc09-1578. Epub 2010 Jan 12. Diabetes Care. 2010. PMID: 20067958 Free PMC article. Clinical Trial.
Diabetes-Induced Cardiomyocyte Passive Stiffening Is Caused by Impaired Insulin-Dependent Titin Modification and Can Be Modulated by Neuregulin-1.
Hopf AE, Andresen C, Kötter S, Isić M, Ulrich K, Sahin S, Bongardt S, Röll W, Drove F, Scheerer N, Vandekerckhove L, De Keulenaer GW, Hamdani N, Linke WA, Krüger M. Hopf AE, et al. Among authors: bongardt s. Circ Res. 2018 Jul 20;123(3):342-355. doi: 10.1161/CIRCRESAHA.117.312166. Epub 2018 May 14. Circ Res. 2018. PMID: 29760016
Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials.
Clowse ME, Wallace DJ, Furie RA, Petri MA, Pike MC, Leszczyński P, Neuwelt CM, Hobbs K, Keiserman M, Duca L, Kalunian KC, Galateanu C, Bongardt S, Stach C, Beaudot C, Kilgallen B, Gordon C; EMBODY Investigator Group. Clowse ME, et al. Among authors: bongardt s. Arthritis Rheumatol. 2017 Feb;69(2):362-375. doi: 10.1002/art.39856. Arthritis Rheumatol. 2017. PMID: 27598855 Free PMC article. Clinical Trial.
Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome: Post Hoc Analyses From the EMBODY Trials.
Gottenberg JE, Dörner T, Bootsma H, Devauchelle-Pensec V, Bowman SJ, Mariette X, Bartz H, Oortgiesen M, Shock A, Koetse W, Galateanu C, Bongardt S, Wegener WA, Goldenberg DM, Meno-Tetang G, Kosutic G, Gordon C. Gottenberg JE, et al. Among authors: bongardt s. Arthritis Rheumatol. 2018 May;70(5):763-773. doi: 10.1002/art.40425. Epub 2018 Apr 12. Arthritis Rheumatol. 2018. PMID: 29381843 Free PMC article.
14 results